Co-Diovan 80 mg/12,5 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

co-diovan 80 mg/12,5 mg apvalkotās tabletes

novartis baltics, sia, latvia - valsartanum, hydrochlorothiazidum - apvalkotā tablete - 80 mg/12,5 mg

Ultomiris Unia Europejska - łotewski - EMA (European Medicines Agency)

ultomiris

alexion europe sas - ravulizumab - hemoglobīnūrija, paroksizmāla - selective immunosuppressants - paroxysmal nocturnal haemoglobinuria (pnh)ultomiris is indicated in the treatment of adult and paediatric patients with a body weight of 10 kg or above with pnh:- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months (see section 5. atypical haemolytic uremic syndrome (ahus)ultomiris is indicated in the treatment of patients with a body weight of 10 kg or above with ahus who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab (see section 5. generalized myasthenia gravis (gmg)ultomiris is indicated as an add-on to standard therapy for the treatment of adult patients with gmg who are anti-acetylcholine receptor (achr) antibody-positive. neuromyelitis optica spectrum disorder (nmosd)ultomiris is indicated in the treatment of adult patients with nmosd who are anti-aquaporin 4 (aqp4) antibody-positive (see section 5. ultomiris is indicated in the treatment of adult patients with paroxysmal nocturnal haemoglobinuria (pnh):- in patients with haemolysis with clinical symptom(s) indicative of high disease activity. - in patients who are clinically stable after having been treated with eculizumab for at least the past 6 months. ultomiris is indicated in the treatment of adult patients with atypical haemolytic uremic syndrome (ahus) who are complement inhibitor treatment-naïve or have received eculizumab for at least 3 months and have evidence of response to eculizumab.

Dipperam HCT 5 mg/160 mg/12,5 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

dipperam hct 5 mg/160 mg/12,5 mg apvalkotās tabletes

sandoz d.d., slovenia - amlodipinum, valsartanum, hydrochlorothiazidum - apvalkotā tablete - 5 mg/160 mg/12,5 mg

Dipperam HCT 10 mg/160 mg/12,5 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

dipperam hct 10 mg/160 mg/12,5 mg apvalkotās tabletes

sandoz d.d., slovenia - amlodipinum, valsartanum, hydrochlorothiazidum - apvalkotā tablete - 10 mg/160 mg/12,5 mg

Dipperam HCT 5 mg/160 mg/25 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

dipperam hct 5 mg/160 mg/25 mg apvalkotās tabletes

sandoz d.d., slovenia - amlodipinum, valsartanum, hydrochlorothiazidum - apvalkotā tablete - 5 mg/160 mg/25 mg

Dipperam HCT 10 mg/160 mg/25 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

dipperam hct 10 mg/160 mg/25 mg apvalkotās tabletes

sandoz d.d., slovenia - amlodipinum, valsartanum, hydrochlorothiazidum - apvalkotā tablete - 10 mg/160 mg/25 mg

Dipperam HCT 10 mg/320 mg/25 mg apvalkotās tabletes Łotwa - łotewski - Zāļu valsts aģentūra

dipperam hct 10 mg/320 mg/25 mg apvalkotās tabletes

sandoz d.d., slovenia - amlodipinum, valsartanum, hydrochlorothiazidum - apvalkotā tablete - 10 mg/320 mg/25 mg

Aclasta Unia Europejska - łotewski - EMA (European Medicines Agency)

aclasta

sandoz pharmaceuticals d.d. - zoledronic acid - osteoporosis; osteitis deformans; osteoporosis, postmenopausal - zāles kaulu slimību ārstēšanai - treatment of osteoporosis: , in post-menopausal women;, in men; , at increased risk of fracture, including those with a recent low-trauma hip fracture. attieksmi pret osteoporozi, kas saistītas ar ilgtermiņa sistēmisko glikokortikoīdu terapija sievietēm pēc menopauzes un vīriešiem paaugstināts risks lūzums. Ārstēšana paget ir slimības ar kaulu.

Aerinaze Unia Europejska - łotewski - EMA (European Medicines Agency)

aerinaze

n.v. organon - desloratadine, pseudophedrine sulfate - rinīts, alerģisks, sezonas - deguna preparāti - simptomātiska ārstēšana sezonas alerģiskas iesnas, kad kopā ar aizlikts deguns.

Eurartesim Unia Europejska - łotewski - EMA (European Medicines Agency)

eurartesim

alfasigma s.p.a. - piperaquine tetraphosphate, artenimol - malārija - antiprostozie līdzekļi - eurartesim ir indicēts nekomplicētas plasmodium falciparum malārijas ārstēšanai pieaugušajiem, bērniem un zīdaiņiem no 6 mēnešiem un vecākiem, kuri sver 5 kg vai vairāk. jāņem vērā oficiālās vadlīnijas par pareizi lietot pretmalārijas aģentu.